ResoTher Pharma

Executive Summary

ResoTher Pharma is a private, clinical-stage biotechnology company headquartered in Copenhagen, Denmark, founded in 2017. The company is pioneering a novel class of peptide-based drugs that harness resolution therapy to actively target inflammation in cardiovascular disease, particularly acute critical-care conditions. By shifting the focus from merely managing inflammation to actively resolving it, ResoTher aims to address significant unmet medical needs in areas such as myocardial infarction and stroke. The company is currently advancing its lead candidate through Phase 2 clinical development, positioning itself as an innovative player in the cardiovascular inflammation space. Its differentiated mechanism of action and strong IP portfolio offer potential for first-in-class therapies that could improve patient outcomes and reduce healthcare burdens. ResoTher's platform has demonstrated encouraging preclinical and early clinical results, suggesting a favorable safety profile and potential efficacy in reducing inflammatory damage. The company is backed by experienced leadership and has attracted interest from strategic investors. However, as a private entity with limited public disclosure, execution risks remain, including successful trial completion, regulatory navigation, and competitive positioning. Pending clinical data readouts and potential partnering opportunities will be critical value inflection points. With a focused pipeline and a clear therapeutic rationale, ResoTher represents a promising but early-stage investment opportunity in the rapidly evolving resolution medicine field.

Upcoming Catalysts (preview)

• H2 2026Phase 2 Top-Line Data Readout for Lead Candidate55% success
• 2026Strategic Partnership or Licensing Deal40% success
• 2026Series B/C Financing Round70% success